Published in Vaccine Weekly, December 7th, 2005
Additionally, the company expects to file an annual report on Form 10-K for the year ended December 31, 2005 and to be current with all of its financial statements in the second quarter of 2006. VaxGen expects to apply for relisting on the Nasdaq as soon as it is current with all of its financial statements.
Since its last update in July 2005, VaxGen has made significant progress toward filing its financial statements. An independent valuation of Celltrion, Inc., VaxGen's minority owned...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly